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Abstract
The ERCC4 protein forms a structure-specific endonuclease involved in the DNA damage response. Different cancer
syndromes such as a subtype of Xeroderma pigmentosum, XPF, and recently a subtype of Fanconi Anemia, FA-Q, have been
attributed to biallelic ERCC4 gene mutations. To investigate whether monoallelic ERCC4 gene defects play some role in the
inherited component of breast cancer susceptibility, we sequenced the whole ERCC4 coding region and flanking
untranslated portions in a series of 101 Byelorussian and German breast cancer patients selected for familial disease (set 1,
n = 63) or for the presence of the rs1800067 risk haplotype (set 2, n = 38). This study confirmed six known and one novel
exonic variants, including four missense substitutions but no truncating mutation. Missense substitution p.R415Q
(rs1800067), a previously postulated breast cancer susceptibility allele, was subsequently screened for in a total of 3,698
breast cancer cases and 2,868 controls from Germany, Belarus or Russia. The Gln415 allele appeared protective against
breast cancer in the German series, with the strongest effect for ductal histology (OR 0.67; 95%CI 0.49; 0.92; p = 0.003), but
this association was not confirmed in the other two series, with the combined analysis yielding an overall Mantel-Haenszel
OR of 0.94 (95% CI 0.81; 1.08). There was no significant effect of p.R415Q on breast cancer survival in the German patient
series. The other three detected ERCC4 missense mutations included two known rare variants as well as a novel substitution,
p.E17V, that we identified on a p.R415Q haplotype background. The p.E17V mutation is predicted to be probably damaging
but was present in just one heterozygous patient. We conclude that the contribution of ERCC4/FANCQ coding mutations to
hereditary breast cancer in Central and Eastern Europe is likely to be small.
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Introduction
An individual’s breast cancer risk is shaped by inherited
variation in genes that normally ensure genome stability through
their function in DNA damage recognition and repair. This
includes the resolution of deleterious DNA structures that result as
a consequence of damage or from abnormal replication and
recombination intermediates. The proteins ERCC4 (also known as
XPF or FANCQ) and ERCC1 form a heterodimeric structure-
specific endonuclease that promotes DNA cleavage at single-
stranded/double-stranded junctions as a prerequisite to the
removal of structures resulting from DNA intra- and interstrand
crosslinks [1–3]. The ERCC1/ERCC4 complex is recruited by
the XPA protein to sites of nucleotide excision repair [4]. ERCC4
activity is regulated by SLX4, a coordinator of structure-specific
endonucleases required for the resolution of Holliday junctions
and interstrand crosslink repair [5]. ERCC4 also interacts with
RAD52, and the binding of RAD52 and ERCC4 concomitantly
stimulates the endonuclease activity of ERCC1/ERCC4 and
attenuates the DNA strand annealing activity of RAD52 during
homologous recombination [6]. Thus, ERCC4 is a versatile
protein that is required for different types of DNA repair.
The ERCC4 gene is located on chromosome 16p13.12, consists
of eleven exons and encodes a 104 kDa protein of 916 amino
acids. Defects of ERCC4 are the cause of xeroderma pigmentosum
complementation group F (XP-F) [MIM:278760], and the XFE
progeroid syndrome (XFEPS) [MIM:610965] which includes
stunted growth and microcephaly. More recently, biallelic
mutations of the ERCC4 gene have been identified as the cause
of Fanconi Anemia type Q and Cockayne syndrome [7,8].
Fanconi Anemia (FA) is a rare recessive disorder characterized by
congenital malformations, progressive bone marrow failure and
predisposition to cancer. Sixteen different FA genes have now
been identified whose products act in a common pathway of DNA
interstrand crosslink repair, and some of them (including BRCA2/
FANCD1, BRIP1/FANCJ, PALB2/FANCN, and RAD51C/FANCO)
have also been described as breast and ovarian cancer suscepti-
bility genes [9,10]. It is still unclear, however, whether ERCC4
gene alterations also play some role in the inherited component of
breast cancer susceptibility. In the present study, we investigated
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the mutational spectrum of the ERCC4/FANCQ coding sequence
in a series of German or Byelorussian patients with familial breast
cancer.
Results
The whole coding region and flanking sequences were analysed
by direct sequencing of the 11 exons of the ERCC4 gene in
genomic DNA samples from 25 German and 38 Byelorussian
breast cancer patients with a family history of disease (Set 1). We
confirmed six known single nucleotide polymorphisms (SNPs) in
both non-coding and coding sequences, including the missense
substitution p.R415Q, and three rare exonic variants, including
the missense substitution p.I73V (Table 1). None of the
substitutions was predicted to affect splicing as judged by
MaxEntScan. Of the two missense substitutions, the p.R415Q
was predicted to be deleterious by CONDEL (Consensus
Deleterious Score 0.905).
Since the p.R415Q substitution turned out to be more common
and had been reported as a potential risk allele [30,31], it was
tested for its association with breast cancer in three independent
case-control studies from Germany, Belarus and Russia. The
p.R415Q allele tended to associate with breast cancer in the
HaBCS series, though with a protective effect of the rare allele
(Table 2). The allelic effect was restricted to ductal breast cancer
(OR 0.67, 95%CI 0.49;0.92; p = 0.003) and was also apparent in
patients with a positive family history (p = 0.02), with high-grade
tumours (p = 0.02) and with positive nodal status
(p = 0.04)(Table 2). However, none of these findings could be
replicated in the other two studies, HMBCS and HUBCS, and the
combined analysis did not confirm a significant association
(Mantel-Haenszel OR 0.94, 95%CI 0.82; 1.08) (Table 2). Because
some SNPs in double-strand break repair genes may also impinge
on prognosis, we further assessed whether the ERCC4*p.R415Q
substitution could affect survival from breast cancer. In the 829
patients for whom follow-up data were available, the presence of
the p.R415Q allele had no detectable effect on the breast cancer
specific survival (HR 0.53; 95% CI 0.26–1.10; p = 0.62) nor on the
overall survival (HR 0.63; 95% CI 0.34–1.17; p = 0.34).
To investigate whether the apparent differences in risk between
the studies could be attributed to second-site mutations in linkage
disequilibrium with p.R415Q, we additionally sequenced the
whole ERCC4 coding region in 12 homozygotes and 26
heterozygotes (Set 2), thus representing 50 p.R415Q alleles
identified during the previous screening. This approach uncovered
two additional missense variants, including a novel p.E17V
substitution (Figure 1). The substitution p.E17V is a non-
conservative missense substitution that is predicted by CONDEL
to be deleterious with a score of 0.903. It is presently unconfirmed
whether this missense variant is indeed pathogenic, as only one
heterozygous patient was identified. The patient who was a
homozygote for p.R415Q, originated from Belarus and had been
diagnosed with an ER-positive lobular breast cancer at the age of
42 years, but had no family history of the disease. The other
missense substitution was a p.E875G substitution that occurred in
the heterozygous state in two unrelated German patients with
bilateral breast cancer but is known as a rare variant (c.2624A.G,
rs1800124) that, although located in the evolutionary conserved
ruvA-like domain, is predicted to be neutral by CONDEL. The
paucity of mutations in the other carriers indicates that any effect
of the p.R415Q allele is unlikely to be explained by second-site
mutations in the ERCC4 coding region.
Discussion
Functional deficiencies in DNA repair are a hallmark of
genomic instability syndromes as well as of mammary carcino-
genesis. Germline mutations in at least four Fanconi Anemia genes
(BRCA2, PALB2, RAD51C, BRIP1) have thus far been found to
contribute to the inherited risk of breast or ovarian cancer [9,10].
The ERCC4 protein is also required for the repair of DNA
interstrand crosslinks and has recently been identified as another
Table 1. Genetic alterations of the ERCC4 gene in German and Byelorussian breast cancer patients.
Location Nucleotide change Codon No. of carriers (frequency) NCBI database annotation
het hom total
Variants in patients with familial breast cancer (Set 1)
Upstream c.230T.A none 22 (.35) 3 (.05) 25 (.40) rs1799797
Exon 1 c.33C.T p.A11A 2 (.03) - 2 (.03) rs3136042
Intron 1 c.207+11G.A none 22 (.35) 3 (.05) 25 (.40) rs762521
Intron 1 c.207+49G.A none 9 (.14) - 9 (.14) rs1799798
Exon 2 c.217A.G p.I73V 1 (.02) . 1 (.02) rs141591400
Exon 8 c.1244G.A p.R415Q 8 (.13) 2 (.03) 10 (.16) rs1800067
Intron 9 c.1905235T.C none 24 (.38) 5 (.08) 29 (.46) rs1799799
Exon 11 c.2505T.C p.S835S 20 (.32) 3 (.05) 23 (.37) rs1799801
Exon 11 c.2655G.A p.T885T 1 (.02) - 1 (.02) rs16963255
Additional variants identified in p.R415Q carriers (Set 2)
Exon 1 c.50A.T p.E17V 1 (.01)* - 1 (.01)* not listed
Exon 11 c.2624A.G p.E875G 2 (.02)* - 2 (.02)* rs1800124
Survey of genetic alterations of the ERCC4 gene identified in a sequencing study of 101 patients selected for familial breast cancer (n = 63, Set 1) or the p.R415Q
haplotype (n = 38, Set 2). Mutations were designated according to the improved mutation nomenclature recommended by the Human Genome Variation Society [www.
hgvs.org/mutnomen/], using the Ensembl transcript ID ENST00000311895 and protein ID ENSP00000310520 for the ERCC4 coding sequence. Rs numbers refer to the
NCBI SNP database [http://www.ncbi.nlm.nih.gov/sites/entrez]. Het, heterozygous; hom, homozygous.
*Percentage refers to the total series of 101 sequenced patients.
doi:10.1371/journal.pone.0085334.t001
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component of the Fanconi Anemia pathway and novel Fanconi
Anemia protein [7,8]. ERCC4 is therefore a plausible candidate
gene to investigate whether inactivating germ-line mutations in its
coding sequence may also contribute to breast cancer risk.
Furthermore a missense polymorphism, p.R415Q, has been
associated with benign breast disease, a potential intermediate
marker of breast cancer risk, and with an increased breast cancer
risk in Europeans [30,31]. The presence of ERCC4 mutations may
also be of therapeutic relevance as inhibitors that target the
ERCC1-XPF complex have been proposed as a novel strategy to
overcome chemoresistance towards cross-linking agents [32]. In
the present work, we have sequenced all exons and flanking non-
coding sequences of ERCC4 in a total of 75 breast cancer patients.
This selected series included an exploratory set of 25 German and
38 Byelorussian patients with a pronounced family history of
breast cancer, and a subsequent validation set of 38 breast cancer
Table 2. Association study of the ERCC4 missense variant p.R415Q in three breast cancer case-control series.
Study ERCC4*p.R415Q genotypes (RR/RQ/QQ) per allele OR (95% CI) ptrend
cases controls
HaBCS (Germany) 808/123/1 827/151/5 0.81 (0.63; 1.03) 0.07
- ductal 529/65/0 . 0.65 (0.48; 0.87) 0.003**
- FH+ve 132/12/0 . 0.50 (0.27; 0.91) 0.02*
- ER+ve 496/74/0 . 0.78 (0.58; 1.04) 0.08
- high grade 265/31/0 . 0.62 (0.42; 0.92) 0.02*
- node+ve 225/28/0 . 0.66 (0.43; 0.99) 0.04*
HMBCS (Belarus) 1721/205/11 1086/141/2 0.99 (0.80; 1.23) 0.95
- ductal 473/60/3 . 1.05 (0.76; 1.41) 0.77
- FH+ve 268/34/3 . 0.98 (0.66; 1.45) 0.54
- ER+ve 853/90/4 . 0.87 (0.67; 1.13) 0.30
- high grade 154/20/1 . 1.07 (0.67; 1.70) 0.77
HUBCS (Russia) 748/75/6 593/62/1 1.08 (0.78; 1.50) 0.66
- ductal 291/24/2 . 0.90 (0.57; 1.42) 0.66
- FH+ve 24/2/0 . 0.78 (0.19; 3.28) 0.73
- high grade 60/8/0 . 1.21 (0.57; 2.59) 0.61
- node+ve 241/19/0 . 0.74 (0.44; 1.24) 0.25
Total 3277/403/18 2506/354/8 0.94 (0.82; 1.08) 0.39
Results from an association study of the missense substitution p.R415Q in case-control series from Germany (HaBCS: 932 cases/983 controls), Belarus (HMBCS: 1,937
cases/1,229 controls) and Russia (HUBCS: 829 cases/656 controls). Minor allele frequency (MAF) in controls was 0.08 in HaBCS and 0.06 in HMBCS, and was 0.06 for each
of both, Russians and Tatars in HUBCS but was lower in the Bashkir subpopulation (MAF 0.01). Per-allele odds ratios were calculated in comparison to the controls for all
breast cancer patients and for specific subgroups after stratification by ductal histology, 1u degree family history of breast cancer, tumour grade (high grade defined as
.2) and – where available - estrogen receptor status and nodal status. Ptrend values were calculated under an additive model using Armitage trend tests. For the total,
Mantel-Haenszel Odds Ratio and p-value were obtained from a combined analysis with stratification by study population.
*p,0.05;
**p-value for ductal histology remained significant after Bonferroni correction.
doi:10.1371/journal.pone.0085334.t002
Figure 1. Identification of a novel missense mutation in the ERCC4 gene. Identification of the missense mutation p.E17V (c.50A.T) in the
ERCC4 gene by direct sequencing (reverse strand). Left panel: wildtype, right panel: heterozygous carrier of p.E17V.
doi:10.1371/journal.pone.0085334.g001
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patients with a homozygous or heterozygous p.R415Q back-
ground.
The two coding variants that were found in the first set of
patients were p.I73V and p.R415Q. The substitution p.I73V is a
conservative missense variant that has been listed in the
1000genomes database with a minor allele frequency of 0.001 in
Europeans and is predicted to be neutral. There is little evidence
to postulate any effect for this variant. More common is p.R415Q,
a known missense polymorphism (rs1800067) encoding a non-
conservative change from arginine to glutamine that is predicted
to be deleterious. This polymorphism has been associated with
benign breast disease [30], and a meta-analysis of seven different
studies comprising 3,910 cases and 3,985 controls had previously
suggested that Arg415Gln may be a low-penetrant risk factor in
the Caucasian ethnicity for developing breast cancer [31].
However, in our screening of three different populations, the
p.R415Q allele tended to associate with breast cancer in only one
study, HaBCS, where the association was restricted to ductal
breast cancer and was in the opposite direction as the risk effect
reported by Ding and co-workers [31]. Since our study has a total
size that is similar to the previously published meta-analysis, we
conclude that the p.R415Q is unlikely to exert a strong effect on
breast cancer risk. Similar conclusions have been drawn for
another SNP (rs744154) in intron 1 of ERCC4 that is weakly
correlated with p.R415Q and failed to be reproduced in larger
studies [23,33].
Additional ERCC4 mutations are unlikely to account for study
heterogeneity, since our resequencing of 12 p.R415Q homozy-
gotes and 26 p.R415Q heterozygotes led to the detection of two
further potential mutations (p.E17V, p.E875G) in three patients,
thereby representing at most some 6% of the sequenced p.R415Q
chromosomes. The substitution p.E17V is a non-conservative
missense substitution that is predicted to be deleterious. The
substitution p.E875G is a non-conservative missense substitution
in a conserved domain but is predicted to be neutral. It is presently
undetermined whether these variants, alone or in combination
with p.R415Q, would indeed be pathogenic, as the heterozygous
patients identified had no strong family history of cancer. For
p.E875G, that is listed with an allele frequency of 0.009
(rs1800124), much larger case-control studies would be required
to clarify any risk association. For p.E17V, that is neither listed in
the 1000genomes project nor in the NCBI SNP database and
appears to be a very rare variant, the potential role of the p.E17V-
p.R415Q double substitution for breast cancer risk, if any, is
expected to be limited.
While this manuscript was under review, an independent study
was published that assessed the frequency of ERCC4 mutations in
Spanish breast cancer patients [34]. Osorio et al. scanned 1,573
breast cancer patients using DHPLC and identified one truncating
mutation and two functionally relevant missense variants. Their
mutation frequency in cases was not different from controls,
suggesting that ERCC4 is not a breast cancer susceptibility gene
[34]. Missense substitution p.R415Q was not addressed specifi-
cally, but as this allele is not uncommon in Spain, mutations
associated with it would have been picked up. Thus, our
observations are in full concordance with results from the Spanish
population.
Altogether, this study did not support a major role for ERCC4
coding variants in familial breast cancer risk, although rare
mutations such as p.E17V could make minor contributions. We
also did not confirm previously suggested associations of the
p.R415Q substitution with an increased breast cancer risk. The
rarity of pathogenic mutations in our study seems to be consistent
with the view that germ-line mutations in the ERCC4/FANCQ
gene might account for only a very small proportion of breast
cancer patients in Central and Eastern Europe.
Methods
Patients
Our study group consisted of two large breast cancer case-
control series, the Hannover Breast Cancer Study (HaBCS) and
the Hannover-Minsk Breast Cancer Study (HMBCS). In addition,
the Hannover-Ufa Breast Cancer Study (HUBCS), served as a
further validation set for the p.R415Q screening.
The HaBCS includes a hospital-based series of 1012 unselected
German breast cancer patients who were treated at the
Department of Radiation Oncology at Hannover Medical School
from 1996–2001. This patient series had been used previously to
determine the frequency and risks of intermediate-penetrance
mutations [11–18], and to study some more common polymor-
phisms in candidate genes by the Breast Cancer Association
Consortium [19–24]. Genomic DNA was available for 965
patients, and follow-up data were available for 829 patients, with
a median follow-up time of 7.6 years. 34 patients were eligible for
the ERCC4 resequencing study on the basis of a family history
score of at least 1.5 (corresponding to at least one first and one
second degree relative with breast cancer). Of those, seven known
carriers of a BRCA1 or BRCA2 mutation and two samples with
small amounts of DNA were excluded. Thus, there remained 25
patients for the initial ERCC4 sequencing study. Population
controls were randomly taken from a cohort of healthy female
German blood donors recruited in 2005 at the same university
hospital.
The HMBCS has also been described previously and has been
subject of genetic association studies of rare susceptibility alleles
[14–16,18,25,26] or common polymorphisms [22,24,27]. Byelor-
ussian cases were 1945 female breast cancer patients who had
been diagnosed during the years 1998–2008 at the Byelorussian
Institute for Oncology and Medical Radiology Aleksandrov N.N.
in Minsk or at one of the regional oncology centers in Gomel,
Mogilev, Grodno, Brest or Vitebsk, respectively. Family history
was available for 97.2% of the cases. Of those, we singled out 40
patients who had a family history score of at least 2 (corresponding
to two first degree relatives, or one first and two second degree
relatives, or one first and one second and two third-degree relatives
with breast cancer). Two patients who were known carriers of a
BRCA1 mutation were excluded. Thus, we remained with 38
patients for the initial ERCC4 sequencing study. Population
controls were taken from a cohort of healthy female Byelorussian
blood donors who had no personal or family history of cancer and
were recruited at the Minsk center during the same time period.
The HUBCS series has also been described previously [18,25].
This series from Russia consisted of 1,059 breast cancer patients
unselected for family history who had been diagnosed during the
years 2000–2007 at the oncological center in Ufa (Bashkortostan).
Healthy population controls included 1,069 volunteers from the
same geographic regions, with a similar ethnic distribution. This
series was used for TaqMan screening only, with a preference
given to samples of mainly European descent.
Mutation analyses
Genomic DNA was isolated from peripheral EDTA blood
samples using standard phenol-chloroform extraction. All coding
exons of the ERCC4 gene were amplified by polymerase chain
reaction using previously reported primer pairs with sequences
flanking the respective exons [7]. 35 cycles of PCR were carried
out using HotStart Taq DNA Polymerase (Qiagen) with 1 min
ERCC4 Mutations in Breast Cancer
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annealing at the primer specific temperature, 1 min extension at
72uC and 1 min denaturation at 94uC. Sequencing reactions were
performed using one of the PCR primers with BigDye v1.1
chemistry, and sequences were evaluated on a Genetic Analyzer
3100 Avant (Applied Biosystems). The missense substitution
p.R415Q was subsequently screened for in three case-control
series using a commercially available TaqMan 59-exonuclease
assay (C___3285104_10, Applied Biosystems) on a 7500 FAST
Genetic Analyzer (Applied Biosystems). Call rates were above 95%
for each study.
Statistical analyses
Genotype data and allele frequencies for missense variant
p.R415Q were tested for consistency with Hardy Weinberg
equilibrium and odds ratios were estimated under additive,
dominant and recessive models using SNP & Variation Suite 7
Software (Golden Helix Inc.). Allele and genotype frequencies
were compared using chi-square tests, or an Armitage trend test in
the additive model. These analyses were performed for the whole
series of patients and for subgroups stratified by family history of
breast cancer, histology, estrogen receptor status, nodal status or
tumour grade. Odds ratios for subgroups were based on a
comparison with the total control series. A two-sided p value ,
0.05 was considered to be significant. For a combined evaluation
of the three series, stratified analyses were run and Mantel-
Haenszel Odds Ratios were calculated using EpiCalc 2000 (www.
brixtonhealth.com/epicalc.html).
In addition, overall survival and breast cancer specific survival
were analysed for HaBCS cases with available follow-up data
(n = 829) with Kaplan Meier statistics using SPSS12 software
(SPSS, Munich). Survival endpoints, measured from the date of
diagnosis, were any death or death from breast cancer for OS or
BCSS, respectively, and alive at last follow-up (censored at 10
years).
Bioinformatic analyses of missense substitutions were performed
using the program CONDEL that combines various tools such as
SIFT, Polyphen2, and MutationAssessor to calculate the consen-
sus deleteriousness score of non-synonymous variations (http://bg.
upf.edu/condel/home). [28]. Possible effects of identified substi-
tutions on splicing were tested using MaxEntScan (http://genes.
mit.edu/burgelab/maxent/Xmaxentscan_scoreseq.html) [29].
Global frequency data were available on the Ensembl website of
the 1000genomes project (www.1000genomes.org).
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